Create personalized user journeys with Omnichannel Marketing as a Service.
Empower your marketing operations with AI and Data.
Adopt a future-proof holistic approach to content strategy.
Leverage a suite of professional services for pharma and life sciences.
Develop and enable adaptable pharma and life sciences marketing content.
Enable format-free marketing with content management platform.
End-to-end platform for content validation and sales force readiness.
AI-powered congress engagement coordinator.
Discover our story, values, and how we're making a positive impact
Explore the heart of our organization and meet the visionary minds
Join the Viseven team and grow your career with us
The Viseven team is about respect, diversity, comfortable working conditions, and equal opportunities for everyone. We explore, evolve, and adapt – together.
Viseven, a digital transformation partner for life sciences, has just launched Lexi, an AI-powered coordinator for smarter event engagement. It was developed to help life sciences, pharma & medtech teams foster impactful engagement with attendees at life sciences events, analyze data, extract actionable insights, and personalize interactions – all in one place, while staying compliant […]
After years of shaping digital excellence in Life Sciences, eWizard and Viseven web presences now come under one roof. As an end-to-end digital commercialization partner for life sciences, Viseven naturally includes eWizard as part of its extensive portfolio of services, and this will now be reflected in the web presence of the two brands. One […]
Global pharma companies appear to hold all the cards in emerging markets — stronger R&D pipelines, higher digital maturity, and the resources to execute at scale. Yet drug accessibility rarely comes down to a single decision at corporate HQ. Behind every market entry lies a more complex reality: localization is not simply translation, and most […]
In pharma, broken processes have a long shelf life. Content workflows are no exception — teams notice the inefficiencies, the duplicated effort, the review cycles that drag on for too long, but the perceived risk of changing anything keeps them from acting on it. The result is a kind of institutional inertia: everyone sees the […]
Would you be okay starting a therapy with a 2.5-star rating for a condition where every moment impacts clinical outcomes? Now imagine coming across a negative patient review, or seeing a trusted HCP publicly question its effectiveness or highlight side effects. Even in oncology, where treatment decisions are guided by HCPs, what patients read online […]
